Blog

Clinical notes from our practice.

Articles on mental health, weight management, hormone therapy, and the connections between them, written from the exam room rather than the marketing department.

๐Ÿ’ง
GLP-1 Side Effects June 6, 2026

Nausea on Wegovy or Zepbound? How we help, and what the eloralintide news really means

Nausea is the most common GLP-1 side effect we see in clinic and a leading reason patients stop. How we address it, and a careful read on eloralintide, the investigational amylin medication in Phase 2.

Read article →
๐Ÿ”ฌ
GLP-1 & Cancer Risk May 29, 2026

GLP-1s and breast cancer: what the ASCO 2026 data means for midlife women

Cleveland Clinic real-world data showed GLP-1 users were 43% less likely to progress to Stage IV breast cancer. A clinician on what it means, what it doesn't, and the family-history questions we hear in clinic.

Read article →
๐Ÿ’Š
Women's Health May 22, 2026

Starting a GLP-1 During Perimenopause When You're Already on a Mood Medication

What we check before starting a GLP-1 in perimenopause while you're on an antidepressant or other mood medication, and how we tell hormones, mood, and the medication apart.

Read article →
โš–๏ธ
Medicare Coverage May 16, 2026

Medicare GLP-1 Bridge Eligibility: BMI Tiers and Conditions That Qualify

A clinician's breakdown of the three BMI eligibility tiers, the specific qualifying conditions for each, the documentation Medicare Part D plans require, and common eligibility edge cases.

Read article →
๐Ÿ›๏ธ
Medicare Coverage May 8, 2026

Medicare GLP-1 Bridge Program: $50/Month Wegovy, Zepbound, Foundayo Starting July 2026

For the first time, Medicare will cover GLP-1 weight loss medications. A clinician's guide to the new bridge program, who qualifies, and how it actually works.

Read article →
๐Ÿง 
Weight Loss & Mental Health May 5, 2026

GLP-1 Medications and Mental Health: What New Research Suggests

A 2026 Lancet Psychiatry study suggests semaglutide may be associated with fewer severe depression and anxiety outcomes. What it means, and what it does not mean, for whole-person care.

Read article →
๐Ÿ“‹
Weight Loss April 30, 2026

Insurance Denied Your Wegovy or Zepbound? What to Do Next

A dual-board NP on why GLP-1 denials happen, what documentation can help, when an appeal is worth it, and what cash-pay options exist if it isn't.

Read article →
๐Ÿง 
Women's Health April 24, 2026

When ADHD Medication Stops Working: Estrogen, the Menstrual Cycle, and Perimenopause

A clinical review of why ADHD stimulants feel weaker in the luteal phase and during perimenopause — with recent research on estrogen, dopamine, and hormone therapy.

Read article →
๐ŸŒฟ
Women's Health April 21, 2026

Is It Perimenopause or Depression? How to Tell the Difference

Symptoms overlap and often coexist. A dual ANCC board-certified NP on how to tell perimenopause and depression apart, and why treating both usually works best.

Read article →
๐Ÿง 
Mental Health March 22, 2026

High-Functioning Anxiety: Symptoms, Causes, and Treatment Options

Functioning doesn't mean thriving. What high-functioning anxiety looks like, why it's so often missed, and what actually treats it.

Read article →
โš–๏ธ
Mental Health March 10, 2026

How Mental Health and Obesity Are Connected

Weight and mental health share a powerful two-way relationship. Why treating one without the other often falls short.

Read article →
๐Ÿ’Š
Weight Loss March 6, 2026

Why Weight Loss Stalls on GLP-1 Medications

Plateaus on Wegovy or Zepbound are common and don't always mean the medication has stopped working. What to check and what to do.

Read article →